Last reviewed · How we verify

Ibuprofen plus Omeprazole

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · FDA-approved active Small molecule

Ibuprofen reduces inflammation and pain by inhibiting cyclooxygenase enzymes, while omeprazole protects the stomach by suppressing gastric acid production.

Ibuprofen reduces inflammation and pain by inhibiting cyclooxygenase enzymes, while omeprazole protects the stomach by suppressing gastric acid production. Used for Osteoarthritis pain with gastric protection, Rheumatoid arthritis pain with gastric protection, Chronic pain conditions requiring NSAID therapy with reduced GI risk.

At a glance

Generic nameIbuprofen plus Omeprazole
SponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug classNSAID plus proton pump inhibitor combination
TargetCOX-1/COX-2 (ibuprofen); H+/K+-ATPase (omeprazole)
ModalitySmall molecule
Therapeutic areaPain management / Gastroenterology
PhaseFDA-approved

Mechanism of action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that blocks COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever. Omeprazole is a proton pump inhibitor that irreversibly blocks the H+/K+-ATPase pump in gastric parietal cells, significantly reducing gastric acid secretion. This combination is designed to provide NSAID efficacy while mitigating the gastrointestinal toxicity (ulcers, bleeding) associated with chronic NSAID use.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: